Find Cancer Clinical Trials Near You

Search our clinical trials

Cancer Treatment Centers of America^® (CTCA) is committed to providing new and innovative treatments for our cancer patients whenever possible. This includes enrolling qualified patients in carefully selected clinical trials for cancer. Clinical trials are a key testing ground for determining the effectiveness and safety of new treatments and drugs for cancer and other diseases. Our doctors may recommend that cancer patients enroll in cancer clinical trials if they meet specific criteria. Cancer trials may offer patients access to treatment options that would otherwise be unavailable to them. Talk to your doctor about whether a cancer trial is a good option for you and ask about the risks and various requirements involved. Use the tool below to find a CTCA^® clinical trial for your cancer type.

Prostate Cancer

CTCA Atlanta CTCA Phoenix CTCA Tulsa

Accepting new patients

Learn more at

clinicaltrials.gov

EA8153: Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel (The CHAARTED2 Trial)

This randomized phase II trial studies how well abiraterone acetate and antiandrogen therapy, with or without cabazitaxel and prednisone, work in treating patients with castration-resistant prostate cancer previously treated with docetaxel that has spread to other parts of the body.

Prostate Cancer

CTCA Philadelphia

Accepting new patients

Learn more at

clinicaltrials.gov

NRG-GU007: Randomized phase II trial of niraparib with standard combination radiotherapy and androgen deprivation therapy (ADT) in high-risk prostate cancer (with initial phase I)

This phase II trial studies the side effects and best dose of niraparib, and to see how well it works in combination with standard of care radiation therapy and hormonal therapy (androgen deprivation therapy) in treating patients with prostate cancer that has a high chance of coming back (high risk).

Prostate Cancer

CTCA Atlanta CTCA Chicago CTCA Philadelphia

Accepting new patients

Learn more at

clinicaltrials.gov

Pfizer C3441021 (TALAPRO-2): A phase 3, randomized, double-blind, placebo-controlled study Of talazoparib with enzalutamide in metastatic castration-resistant prostate cancer

This study compares radiographic progression free survival (rPFS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with talazoparib plus enzalutamide versus enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.